Trial Profile
Phase 2 Trial of Alemtuzumab and Dose-Adjusted Epoch in Chemotherapy Naive Aggressive T and NK-Cell Lymphomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Feb 2022
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Vincristine
- Indications T-cell lymphoma
- Focus Adverse reactions
- 03 Feb 2022 Status changed from active, no longer recruiting to completed.
- 03 Feb 2022 Status changed from active, no longer recruiting to completed.
- 08 Feb 2021 Planned End Date changed from 1 Jan 2021 to 1 Jan 2022.